INOCA and MINOCA Coronary Vasomotor Disorders - Diagnosis and Treatment
Pursue invasive coronary function testing (CFT) at the time of coronary angiography when non-obstructive disease is identified, as this directly identifies the underlying mechanism and enables targeted, endotype-specific therapy that improves symptoms and quality of life. 1
Diagnostic Criteria
MINOCA Definition
MINOCA requires three specific criteria 2:
Meets AMI criteria per the fourth universal definition:
- Troponin elevation with at least one value >99th percentile
- PLUS at least one of:
- Symptoms of myocardial ischemia
- New ischemic ECG changes
- Development of pathological Q waves
- Imaging evidence of new loss of viable myocardium or regional wall motion abnormalities
- Coronary thrombus on angiography or autopsy
No obstructive CAD (≥50% stenosis) in any epicardial artery, and no overlooked obstructive disease (SCAD, embolus)
Exclusion of non-ischemic mimickers (myocarditis, Takotsubo cardiomyopathy)
INOCA Definition
INOCA encompasses chronic angina or ischemia with non-obstructive coronary arteries (<50% stenosis), caused by coronary microvascular dysfunction, epicardial vasospasm, myocardial bridging, or diffuse atherosclerosis 1.
Pathophysiology - Key Mechanisms
Understanding the specific mechanism is critical because treatment differs substantially:
Atherosclerotic causes (approximately two-thirds of MINOCA) 2:
- Plaque disruption (rupture, erosion, calcific nodules)
- Thrombus formation with distal embolization
- Risk factor profile similar to obstructive MI
Non-atherosclerotic causes 2:
- Epicardial coronary vasospasm: Vascular smooth muscle hyperreactivity; >90% demonstrate vasoconstriction during acetylcholine or ergonovine testing
- Coronary microvascular dysfunction (CMD): Found in nearly half of INOCA patients; disruption of nitric oxide, adenosine, and prostacyclin signaling 3, 4
- SCAD: Primarily affects women (>90%); coronary intramural hematoma causing luminal obstruction; accounts for 40% of MI in women <50 years and 14-43% of pregnancy-related MI 2
- Thromboembolism
Diagnostic Algorithm
Initial Non-Invasive Workup
When coronary angiography shows non-obstructive disease 3:
- ECG (look for ischemic changes, Q waves)
- Serial troponins
- Echocardiography (regional wall motion abnormalities, LV function)
- Coronary CT angiography (assess for diffuse atherosclerosis, myocardial bridging)
Invasive Coronary Function Testing (CFT) - Class I Recommendation
The 2024 ESC guidelines provide a Class I recommendation for CFT availability at initial coronary angiography 1. This is the critical diagnostic step that changes management.
When to perform CFT 1:
- At time of initial coronary angiography when mechanisms are uncertain after non-invasive testing
- In established INOCA/MINOCA patients with persistent symptoms and poor quality of life despite medical therapy
Intracoronary imaging (OCT or IVUS):
- Identifies plaque disruption, SCAD, thrombus invisible to conventional angiography
- Essential for SCAD diagnosis when angiography is equivocal
Coronary flow reserve (CFR) and index of microcirculatory resistance (IMR):
- Diagnoses coronary microvascular dysfunction
- CFR <2.0 or elevated IMR indicates CMD
Acetylcholine provocative testing:
- Identifies epicardial and microvascular spasm
- Positive in >50% of tested patients 7
- Assesses endothelial dysfunction
Cardiac MRI - Non-Invasive Gold Standard
Cardiac MRI is mandatory for tissue characterization 7:
- Confirms ischemic injury pattern
- Excludes non-ischemic mimickers (myocarditis, Takotsubo)
- Provides independent prognostic information
- Reclassifies diagnosis in substantial proportion of cases
Mechanism-Based Treatment Strategy
Treatment must be guided by the specific endotype identified on CFT 1, 3. Empiric therapy without mechanism identification is inadequate.
For Plaque Disruption/Atherosclerotic Mechanisms 7:
- Dual antiplatelet therapy (aspirin + P2Y12 inhibitor)
- High-intensity statin therapy
- ACE inhibitors or ARBs
- Beta-blockers
- Aggressive cardiovascular risk factor modification
For Epicardial Coronary Vasospasm 2, 3:
- Calcium channel blockers (first-line; long-acting dihydropyridines or diltiazem)
- Long-acting nitrates
- Avoid beta-blockers (may worsen vasospasm)
- Smoking cessation (critical - smoking is major risk factor)
For Coronary Microvascular Dysfunction 3, 8:
- ACE inhibitors or ARBs (improve endothelial function)
- Calcium channel blockers
- Beta-blockers (particularly if tachycardia present)
- Ranolazine (improves microvascular function)
- Statins (pleiotropic endothelial effects)
- Emerging: Rho-kinase inhibitors 8
For SCAD 2:
- Conservative management (preferred approach)
- Avoid anticoagulation and aggressive antiplatelet therapy
- Beta-blockers for blood pressure control
- Avoid percutaneous intervention unless ongoing ischemia
Combined Mechanisms
Many patients have overlapping pathophysiology 5. Tailor combination therapy based on CFT findings:
- CMD + vasospasm: Calcium channel blocker + ACE inhibitor + ranolazine
- Atherosclerotic + CMD: Statin + antiplatelet + ACE inhibitor + ranolazine
Critical Pitfalls to Avoid
Discharging without definitive diagnosis: Approximately 50% of centers lack dedicated diagnostic pathways 9. This leads to therapeutic inertia and poor outcomes.
Assuming benign prognosis: INOCA and MINOCA carry significant risk of MACE, MI, and heart failure 8. These are not benign conditions.
Missing SCAD on initial angiography: Small percentage not clearly recognized; requires OCT/IVUS for intramural hematoma 2. Misclassification as MINOCA leads to inappropriate anticoagulation.
Empiric therapy without mechanism identification: Only 25% of centers perform advanced invasive testing 9. CFT-guided therapy improves outcomes compared to standard care (PROMISE trial) 7.
Using beta-blockers for vasospasm: May paradoxically worsen vasospasm by unopposed alpha-adrenergic vasoconstriction.
Prognostic Implications
Both INOCA and MINOCA require dedicated follow-up 9. Currently only 20% are followed in dedicated outpatient clinics, which is inadequate given:
- Significant MACE risk comparable to obstructive CAD
- Risk of progression to ischemic cardiomyopathy 3
- Need for ongoing symptom management and quality of life optimization
The stratified, imaging-guided approach improves patient-centered outcomes compared to standard care, as demonstrated in the PROMISE trial 7.